Dermatological adverse drug reactions due to systemic medications – a review of literature
Keywords:
Cutaneous adverse drug reactions, causality assessment, Naranjo algorithm, South AsiaAbstract
Cutaneous adverse drug reactions (ADRs) affect 2-3% of hospitalized patients. These reactions can arise as a result of immunologic or non-immunologic mechanisms. Extremes of age, female sex, previous history of ADRs and environmental factors are the major risk factors. The severity of the cutaneous ADRs may vary from a mild itching to a life threatening Stevens-Johnson syndrome (SJS). In general, most are usually mild and respond to topical treatment. Different skin diseases and cutaneous manifestation of systemic diseases should be ruled out before diagnosing a cutaneous ADR. In order to establish the causal relationship between the offending drug and the reaction, causality assessment should be carried out. The Naranjo algorithm is widely used to determine the causality of an ADR. The cessation of the offending agent, along with the use of systemic and topical steroids, antipruritic agents and oral antihistamines may be helpful in the management. Patients with extensive skin involvement should be cared for as burns patients. High risk patients should be counseled regarding the possibility of developing a cutaneous ADR during the course of treatment and the strategies to be followed upon occurrence of a cutaneous ADR.ÂReferences
Edwards RI, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9.
Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
Bigby M, Jick S, Jick H, Amdt K. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Survelliance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256: 3358-63.
Leape LL, Brennam TA, Laird N et al. The nature of adverse events in hospitalized patients study II. N Engl J Med 1991; 324: 377-84.
Bates DW, Spell N, Cullen DJ, et al. The cost of adverse drug events in hospitalized patients. JAMA 1997; 227: 307-11.
Classen DC, Pestotnik SL, Evans RS et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs and attributable mortality. JAMA 1997; 277: 301-6.
Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol 1998; 37: 833-8.
Puavilai S, Choonhakarn C. Drug eruptions in Bangkok: a 1-year study at Ramathibodi Hospital. Int J Dermatol 1998; 37: 747-51.
Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents--a 6 year series from Chandigarh, India. J Postgrad Med 2001; 47: 95-9.
Thankappan TP, Zachariah J. Drug-specific clinical pattern in fixed drug eruptions. Int J Dermatol 1991; 30: 867-70.
Noel MV, Sushma S, Guido S. Cutaneous adverse drug reactions in hospitalized patients in a tertiary care center. Indian J Pharmacol 2004; 36: 292-5.
Pudukadan D, Thappa DM. Adverse cutaneous drug reactions: clinical pattern and causative agents in a tertiary care center in South India. Indian J Dermatol Venereol Leprol 2004; 70: 20-4.
Sushma M, Noel MV, Ritika MC, James J, Guido S. Cutaneous adverse drug reactions: a 9- year study from a South Indian hospital. Pharmacoepidemiol Drug Saf 2005;14: 567-70.
Dubey AK, Prabhu S, Shankar PR et al. Cutaneous adverse drug reactions to modern medicines and initial experiences from a Spontaneous adverse drug reaction reporting program in a tertiary care teaching hospital of Western Nepal. J Pak Assoc Dermatol 2005; 15: 222-6.
Subish P, Mishra P, Gupta S, Bista D, Anupa KC, Bhandari RB et al.. Pharmacoenonomic impact of cutaneous adverse drug reactions - results from the regional pharmacovigilance center, western Nepal. Abstract presented at 5th Annual Conference of Society of Pharmacovigilance India, 12-13 November 2005, LM. College of Pharmacy, Ahmedabad, India.
Shrestha DP, Gurung D, Kumar A. Severe cutaneous adverse drug reactions: an evidence based approach. J Institute Med 2005; 27: 21-5.
Stern RS, Chosidow OM, Wintroub BU. Cutaneous drug reactions. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison’s Principles of Internal Medicine, 15th edn. New York: McGraw-Hill; 2001. p. 336-42.
Bates DW, Leape L. Adverse drug reaction. In: Caruthers SG, Hoffman BB, Melmon KL, Nierenberg DW, eds. Morreli’s Clinical Pharmacology. Boston: McGraw-Hill; 2000. p. 1223-57.
Blacker K, Stern R, Wintroub BU. Cutaneous reactions to drugs. In: Fitzpatrick TB, Eisen A, Wolff K et al., eds. Dermatology in General Medicine. New York: McGraw-Hill; 1993. p. 1783-94.
Wilson K. Sex-related difference in drug disposition in man. Clinical Pharmacokinet 1984; 9: 189-202.
Smidt NA, McQueen EG. Adverse reactions to drugs: a comprehensive hospital in-patient survey. N Z Med J 1972; 76: 397-401.
Inamdar AC, Palit A. Serious Cutaneous adverse drug reactions: Pathomechanisms and their implications to treatment. Indian J Dermatol Venereol Leprol 2003; 69: 205-8.
Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977; 21: 247-54.
Kramer MS, Leventhal JM, Hutchinson TA et al. An algorithm for the operational assessment of adverse drug reactions. Background, description and instructions for use. JAMA 1979; 242: 623-32.
Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
Blaiss MS, de Shazo RD. Drug allergy. Pediatr Clin North Am 1988; 35: 1131-47.
Park BK, Coleman JW. The immunological basis of adverse drug reactions. A report on a symposium held in Liverpool on 6th April 1988. Br J Clin Pharmacol 1988; 26: 491-5.
Kalish RS. Drug eruptions: a review of clinical and immunological features. Adv Dermatol 1991; 6: 221-37.
Sharma VK, Sethuraman GG. Adverse cutaneous reactions to drugs: an overview. J Postgrad Med 1996; 42: 15-22.
Champion RH, Roberts SOB, Carpenter RG et al. Urticaria and angio-edema: A review of 554 patients. Br J Dermatol 1969; 81: 88-97.
Black AK, Greaves MW, Champion RH. The urticarias 1990. Br J Dermatol 1991; 124: 100.
Healy DR, Sahai JV, Fuller SH. Vancomycin induced histamine release and “Red man syndromeâ€. Comparison of 1 and 2 hour infusions. Antimicrob Agents Chemother 1990; 34: 550.
Narth FC, Kettlekamp N, Hirschman CA. Comparison of cutaneous and in vitro histamine release by muscle relaxants. Anesthesiology 1987; 66: 543.
Slater EE, Werrill DD, Guess HA. Clinical profile of angioedema associated with angiotensin converting enzyme inhibition. JAMA 1988; 260: 967.
Lepage V, Douay C, Mallet C. Erythema multiforme is associated to HLA-Aw33 and Drw53. Tissue Antigens 1988; 32: 170-5.
Imafuku S, Kokuba H, Aurelian L et al. Expression of herpes simplex virus DNA fragments located in epidermal keratinocytes and germinative cells is associated with the development of erythema multiforme lesions. J Invest Dermatol 1997; 109: 550-6.
Carroll OM, Bryan PA, Robinson RJ. Stevens-Johnson syndrome associated with long acting sulfonamides. JAMA 1966; 195: 691-3.
Hardie RA, Savin JA. Drug-induced skin diseases. Br Med J 1979; 1: 935-7
Tonnesen MG, Harrist TJ, Wintroub BU et al. Erythema multiforme: Microvascular damage and infiltration of lymphocytes and basophils. J Invest Dermatol 1983; 80: 282-6.
Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis and severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997; 24: 726-9.
Wolkenstein P, Revuz J. Drug-induced severe skin reactions: incidence, management and prevention. Drug Saf 1995; 13: 56-68.
Lyell A. A review of toxic epidermal necrolysis in Britain. Br J Dermatol 1967; 79: 662- 71.
Beers MH, Berkow R, eds. The Merck Manual of Diagnosis and Therapy, 17th edn. New Jersey: Merck Research Laboratories; 1999.
Magee P. Drug-induced skin disorders. In: Walker R, Edwards C, eds. Clinical Pharmacy and Therapeutics, 3rd edn. Phildelphia: Churchill Livingstone; 2003; 843-52.
Daoud MS, Schanbacher CF, Dicken DH. Recognizing cutaneous drug eruptions. Reaction patterns provide clues to causes. Postgrad Med 1998; 104: 101-4, 107-8, 114-5.
